| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 35.06 | 134 |
| Intrinsic value (DCF) | 10.55 | -30 |
| Graham-Dodd Method | 5.39 | -64 |
| Graham Formula | 14.61 | -2 |
Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ.DE) is a leading German company specializing in isotope technology for medical, scientific, and industrial applications. Headquartered in Berlin, the company operates through two key segments: Medical and Isotope Products. The Medical segment focuses on innovative radioactive implants for prostate cancer treatment and uveal melanoma, alongside radiopharmaceuticals and laboratory equipment. The Isotope Products segment provides radiation sources for imaging, material analysis, and environmental monitoring, serving industries from healthcare to homeland security. With a strong presence in global markets, Eckert & Ziegler combines cutting-edge research with practical applications, positioning itself as a critical player in the medical devices sector. The company's commitment to precision and safety in radiation-based solutions makes it a trusted partner in healthcare and industrial innovation.
Eckert & Ziegler presents a compelling investment opportunity due to its niche expertise in isotope technology and radiopharmaceuticals, sectors with growing demand driven by advancements in cancer treatment and diagnostic imaging. The company's diversified revenue streams from medical and industrial applications mitigate sector-specific risks. However, investors should consider the inherent volatility (beta of 1.578) and regulatory risks associated with radioactive materials. With a market cap of approximately €1.31 billion and solid financials (€295.85M revenue, €33.28M net income in the latest period), the company demonstrates stability. The dividend yield (€0.50 per share) adds appeal for income-focused investors, though capital expenditures and debt levels warrant monitoring.
Eckert & Ziegler's competitive advantage lies in its specialized expertise in isotope technology, a field with high barriers to entry due to regulatory and technical complexities. The company's dual focus on medical and industrial applications diversifies its revenue base while leveraging cross-segment synergies. In the Medical segment, its proprietary radioactive implants (e.g., prostate seeds and eye applicators) face limited direct competition, though broader radiopharmaceutical players could encroach. The Isotope Products segment competes in a more fragmented market but benefits from precision calibration and security applications. The company's German engineering reputation and compliance with stringent EU/US regulations strengthen its global positioning. However, reliance on nuclear material supply chains and evolving radiation safety standards pose risks. Competitors range from large-cap medtech firms to niche isotope suppliers, but Eckert & Ziegler's integrated approach—combining manufacturing, R&D, and regulatory expertise—differentiates it in targeted niches.